IQVIA_Rules_Based_Medicine_Logo - rgb

(+01) 512 835 8026

Email us

Type your search term and press "enter."

Vascular endothelial growth factor receptor 3

Vascular endothelial growth factor receptor 3

Vascular endothelial growth factor receptor 3 (VEGFR-3) is a member of the Class III subfamily of receptor tyrosine kinases plays an essential role in angiogenesis. Expression is almost exclusively restricted to endothelial cells. It acts as a cell-surface receptor for VEGF-A, VEGF-C and VEGF-D and it plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. VEGFR-2 promotes proliferation, survival, migration, and differentiation of endothelial cells. It promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGF-A, VEGF-C and/or VEGF-D. Isoform 2 plays an important role as negative regulator of VEGF-A and VEGF-C-mediated lymphangiogenesis by limiting the amount of free VEGF-A and/or VEGF-C and preventing their binding to FLT4. It modulates FLT1 and FLT4 signaling by forming heterodimers. The binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate in addition to the activation of protein kinase C. It also mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway.

Swiss-Prot Accession Number: P35916


Bibliography

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma (2021) Lee CH, Motzer RJ, Glen H, Michaelson MD, Larkin J, Minoshima Y, Kanekiyo M, Ikezawa H, Sachdev P, Dutcus CE, Funashashi Y, Voss MH British Journal of Cancer

medical_services Therapy Indications

Circulating biomarkers from the phase I trial of sirolimus and autophagy inhibition for patients with lymphangioleiomyomatosis (SAIL). (2018) Lamattina AM, Taveira-Dasilva A, Goldberg HJ, Bagwe S, Cui Y, Rosas IO, Moss J, Henske EP, El-Chemaly S Chest Journal

medical_services Therapy Indications